AbbVie increased its 2026 sales forecast to $67.8 billion and raised its dividend.

ABBV · AbbVie Inc.

The AI's read

This points to stronger sales and profit across much of AbbVie’s business. Skyrizi, Rinvoq, and neuroscience products grew, and the company raised its forecasts. Humira, Imbruvica, and aesthetics sales fell. Growth in other areas was strong enough for AbbVie to raise its company-wide forecasts despite those declines.